
    
      CARADERM is a French national multidisciplinary project which will prospectively enroll from
      37 French centers any patient presenting with Merkel cell carcinoma, advanced basal cell
      carcinoma requiring systemic treatment or cutaneous adnexal carcinoma.

      A structured and centralized database of clinical monitoring of patients will be established.
      Information captured will include clinical constitutional factors, factors linked to primary
      carcinoma, factors linked to lymph node involvement, "American Joint Committee on Cancer"
      (AJCC) stage at inclusion, recurrence patterns, therapeutic interventions (medical, surgical,
      radiotherapy and palliative strategies) with evaluation of response, date of death, date of
      latest news.
    
  